SCHEMBL6785193

SCHEMBL6785193

C/C(=C/C(=O)Nc1ccc(NS(C)(=O)=O)cc1C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.69
DEGS1 O15121 1/20 0.43
ALDH1A1 P00352 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
DHODH Q02127 1/20 0.41
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GPR27 Q9NS67 1/20 0.40
MAPK10 P53779 1/20 0.40
F10 P00742 1/20 0.40
LTB4R Q15722 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ABCB1 P08183 1/20 0.40
AKR1C3 P42330 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6786381 0.92 TERT (0.69) TERTDEGS1ALDH1A1MEN1KMT2A
SCHEMBL6786986 0.90 TERT (0.67) TERTALDH1A1MEN1KMT2AKDM4E
SCHEMBL6788177 0.88 TERT (0.55) TERTALDH1A1HPGDKDM4EMAPK10
SCHEMBL6785515 0.88 TERT (0.63) TERTDEGS1ALDH1A1MEN1KMT2A
SCHEMBL6781944 0.87 TERT (0.75) TERTDEGS1ALDH1A1MEN1KMT2A
SCHEMBL6786594 0.85 TERT (0.72) TERTDEGS1MEN1KMT2ASMN1; SMN2
SCHEMBL6786810 0.84 TERT (0.71) TERTDEGS1KMT2ADHODHKDM4E
SCHEMBL6787659 0.84 TERT (0.56) TERTALDH1A1HPGDKDM4EMAPK10
SCHEMBL4024783 0.84 TERT (0.80) TERTDEGS1ALDH1A1MEN1KMT2A
SCHEMBL4020313 0.84 TERT (0.69) TERTDEGS1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885DEGS1 2701/4885ALDH1A1 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.